Transport Delivers Unprecedented Levels Of Acyclovir With Novel Five Percent Gel Formulation
Transport Pharmaceuticals, Inc., a leader in combination drug/medical devices for the topical treatment of dermatological conditions, today announced preliminary results from a recently completed Phase I safety and pharmacokinetic study with the SoloVir(TM) electrokinetic transdermal system, being developed for the treatment of herpes labialis, or cold sores. The TPI-H-111 study, which was conducted in 32 normal volunteers, was the first clinical application of the new SoloVir(TM) combination product featuring single-use drug cartridges containing Transport’s novel, five-percent acyclovir gel formulation. Although treatment of a herpetic episode with the SoloVir(TM) system will consist of a single ten minute treatment, each subject received four treatments over the course of two days in this study designed to assess safety and pharmacokinetics.
